Maharashtra FDA Cancels Cipla Unit’s Pune Warehouse Drug-Sale Licences Over Alleged Irregularities
The fresh order concerns the Wadki warehouse of Cipla Pharma & Life Sciences. The regulator cites alleged packaging, storage and record-keeping lapses, while Cipla disputes the decision.
The Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd’s carrying and forwarding warehouse at Wadki in Pune, citing alleged irregularities involving medicine packaging, storage, documentation and stock management.
The fresh order was issued on 1 October 2026 and announced by the regulator on 2 October. It follows renewed proceedings after the earlier action against the facility was withdrawn in accordance with Bombay High Court directions.
Cipla has disputed the decision, maintained that the warehouse follows applicable protocols and said it is reviewing the order and evaluating its options. The development concerns a specific distribution facility operated for the Cipla unit.
A Fresh Order Following Renewed Proceedings
According to the FDA’s statement, as reported by news organisations, the latest decision followed consideration of the company’s written explanation, submissions at a hearing, inspection findings and available records.
The order was issued by the Assistant Commissioner of Drugs and licensing authority in FDA Pune’s Division 3. The regulator described the October decision as a fresh determination after completing proceedings following the High Court’s intervention. The reported timeline sets out the sequence.
| Date | Development |
|---|---|
| August 2026 | Earlier licence-cancellation action; the proceedings were subsequently withdrawn following Bombay High Court directions. |
| 4 September 2026 | The FDA issued a revised show-cause notice. |
| 11 September 2026 | Cipla submitted its written response. |
| 21 September 2026 | The company received an opportunity for a personal hearing. |
| 1 October 2026 | The licensing authority issued the fresh cancellation order. |
| 2 October 2026 | The FDA announced the action publicly, and Cipla responded. |
The October order therefore represents a new stage in the dispute. Reports about the earlier withdrawal do not describe the outcome of the renewed proceedings.
Reactin Plus Packaging Is Central to the Case
One of the FDA’s principal objections concerns Reactin Plus Tablets, described in the reports as a Schedule H prescription medicine.
Officials said its packaging included pain-relief claims and a human illustration showing areas where the medicine was promoted as providing relief. The regulator questioned whether the wording and illustrations complied with applicable requirements.
According to the FDA, these findings raised an issue of misbranding under the Drugs and Cosmetics Act, 1940. These are the regulator’s stated findings; Cipla’s response disputes the regulatory decision.
The Warehouse Deficiencies Alleged by the FDA
The regulator’s reported statement identifies several operational and documentation issues at the premises:
- Storage and cleanliness: Medicine cartons allegedly stood directly on the floor because pallets or racks were insufficient. Inspectors also reported dust accumulation and cleanliness deficiencies.
- Expired medicines: The FDA cited inadequate segregation of expired stock and missing procedures or records for its disposal.
- Documentation: Officials reported that the Form 35 inspection book was unavailable and identified shortcomings in purchase and sales-invoice documentation.
- Inventory records: The regulator cited differences between computerised or SAP records and physical stock, including antibiotics.
The FDA said using a digital inventory system did not remove the establishment’s obligations concerning accurate records, physical stock, storage and inspection documents. Its allegations therefore concern both recorded information and conditions at the warehouse.
Cipla Disputes the Decision
Cipla described the FDA’s action as disappointing. In its response reported by NDTV Profit, the company said the Wadki facility follows distribution and storage protocols and the relevant standards for digital record-keeping.
The company said it was examining the order and considering its options. Its stated position is therefore at odds with the FDA’s assessment. The response did not announce a specific appeal, an interim court order or a timetable for resolving the dispute.
Cipla also reaffirmed its commitment to quality, patient safety and continued access to medicines for patients and healthcare providers.
Why the Role of the Drug Marketer Matters
The FDA also examined the establishment’s obligations as the marketer of the medicine. It said those responsibilities could not be avoided simply by referring to the manufacturer’s role.
The wider legal framework expressly addresses this relationship. Rule 84E, introduced through the Drugs and Cosmetics Amendment Rules of 2020, assigns responsibility for drug quality and other regulatory compliance to a marketer alongside the manufacturer. The amendment took effect on 1 March 2021.
This provides context for the regulator’s attention to the marketer. Whether the alleged breaches are established in this particular dispute remains a matter for the applicable regulatory and legal process.
The Scope of the Cipla Pune Warehouse Decision
The licences identified in the reports relate to the Wadki carrying and forwarding warehouse. The reported decision does not establish a companywide manufacturing shutdown.
A carrying and forwarding warehouse forms part of a medicine distribution network. An interruption at such a facility can create operational questions about stock handling and how orders will be fulfilled.
The actual effect depends on the order’s terms and any authorised arrangements made in response. The reports reviewed do not quantify a revenue impact or establish a nationwide medicine shortage arising from this order.
Further operational information would be needed to assess changes in delivery schedules or the extent of any disruption.
Why Distribution Compliance Deserves Attention
The case highlights a wider operational issue for pharmaceutical businesses: protecting medicine quality requires controls throughout storage and distribution.
The World Health Organization’s guidance covers wholesalers, logistics providers and forwarding agents, as well as manufacturers. It calls for documented quality systems and procedures, and says distribution records should contain enough detail to support a recall when required.
These principles explain why warehouse practices and documentation form part of medicine oversight.
For the industry, the practical implication is that warehouse reviews need to test how procedures work on the ground. Records, stock controls and staff practices must operate together to make the movement and condition of medicines traceable.
What to Watch Next
Attention now turns to Cipla’s chosen response and any subsequent decision by a competent authority or court. A confirmed appeal, interim relief, corrective measures or licence restoration would each represent a material development in the dispute.
The business impact will become clearer as the regulatory process and the company’s operational response develop. For distributors and healthcare providers, the key issues will be the status of the warehouse’s licences and the arrangements for continued supply through authorised channels.
For more insights navigate: PressPire | Stories That Shape the Future
Read previous article here: takeme2space-ai-satellite-moi-1a/
Follow PressPire on Facebook | Instagram | LinkedIn | YouTube
PressPire | Stories That Shape the Future
